Company Profile

Chimerocyte Inc
Profile last edited on: 10/7/2019      CAGE: 7XPK8      UEI: MRUSKCJLLEB7

Business Identifier: Detection and quantification of allogeneic cells
Year Founded
2016
First Award
2018
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2451 Perkins Lane West
Seattle, WA 98199
   (206) 432-2736
   N/A
   www.chimerocyte.tech
Location: Single
Congr. District: 07
County: King

Public Profile

Spun out of Fred Hutchinson Cancer Research Center, Seattle, WA and housed in CoMotion Labs at University of Washington, Chimerocyte is structured around development of molecular technologies to detect and quantify allogeneic cells and/or DNA at levels of sensitivity and specificity that are not reached by currently available techniques. The effort is to develop a highly sensitive quantitative chimerism test for use in clinical diagnostics and other scientific research. To date, (patent pending) work has yielded panel of several highly-sensitive and polymorphism-(HLA and other genes)-specific assays, with limit-of-detection reaching ?1:100,000. With transfer of the technology into a clinical application: chimerism monitoring post allo-transplantation, the company is extending development and validation of assays to detect and quantify allogeneic cells (chimerism) and evaluating the clinical significance of this technology for leukemia patients treated by allogeneic hematopoietic cell transplantation.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 2 Army $1,266,371
Project Title: Ions to treat trauma and Covid-19
2019 2 NIH $299,704
Project Title: Highly Sensitive Chimerism Testing to Detect Early Leukemia Relapse Post-Allo-Transplantation

Key People / Management

  Sami Barna Kanaan -- Founder

  Michael Morrison

  J Lee Nelson -- Chief Communication Officer

Company News

There are no news available.